Article Versions Notes

Sato M, Tamura Y, Kaga H, Yamasaki N, Kiya M, Kadowaki S, Sugimoto D, Funayama T, Someya Y, Kakehi S, et al. Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes. Biomedicines. 2021; 9(9):1154. https://doi.org/10.3390/biomedicines9091154

Sato, Motonori, Yoshifumi Tamura, Hideyoshi Kaga, Nozomu Yamasaki, Mai Kiya, Satoshi Kadowaki, Daisuke Sugimoto, Takashi Funayama, Yuki Someya, Saori Kakehi, and et al. 2021. "Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes" Biomedicines 9, no. 9: 1154. https://doi.org/10.3390/biomedicines9091154

Sato, M., Tamura, Y., Kaga, H., Yamasaki, N., Kiya, M., Kadowaki, S., Sugimoto, D., Funayama, T., Someya, Y., Kakehi, S., Nojiri, S., Satoh, H., Kawamori, R., & Watada, H. (2021). Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes. Biomedicines, 9(9), 1154. https://doi.org/10.3390/biomedicines9091154